Roche has received US FDA approval for Vabysmo, an antibody-filled preloaded syringe, to treat neovascular or "wet" age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). Although pricing details were not disclosed, the product will be available soon.
Vabysmo, also known as "faricimab," is the only bispecific antibody approved for treating the eye. The company claims that it has demonstrated rapid and robust vision improvements and retinal drying in nAMD, DME, and RVO. This single-use preloaded syringe can be readily used by retina specialists.
Analyst QuickTake: To date, Vabysmo has been approved in over 95 countries for nAMD and DME, and many other countries including the US and Japan for RVO. Several other health authorities worldwide are reviewing the product for approval. Over 4 million doses of Vabysmo have been distributed globally since its initial US approval in 2022.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.